Autopsy report · NCT01741142

Efficacy and Safety Study of ABT-436 in Major Depressive Disorder

“Decision based on strategic determination; not safety.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 10 months after it had already started.
• Ran for about 3 years 7 months before it stopped.
• 19 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

AbbVie (prior sponsor, Abbott)

Sponsor type

Industry

Conditions

Major Depressive Disorder

Interventions

ABT-436; Escitalopram; Placebo

Participants

19

Sites

18

Countries

United States

Trials that died the same way

• Investigational Study of Delayed Release Metformin
  “Strategic company decision - not related to a safety concern” (82% match in meaning)
• A Single and Multiple Ascending Dose Study of JNJ-64457744
  “Strategic business decision, not due to safety concerns” (82% match in meaning)
• The KHENERGYC Study
  “Strategic company decision - not related to safety concerns” (81% match in meaning)
• A Study of RBI-4000 in Healthy Participants
  “Strategic business decision (not related to safety, efficacy, or quality)” (79% match in meaning)
• Efficacy and Time and Resources for Hylenex-facilitated SC Rehydration Versus ORT for Dehydrated Children in the Emergency Department (ED)
  “Strategic business decision (not related to safety or efficacy concerns)” (79% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.